Institut National De La Sante Et De La Recherche Medicale

Université Paul Sabatier (toulouse Iii)

Centre National De La Recherche Scientifique

Institut Curie

Institut Claudius Regaud

Universite Paul Sabatier

Aurelien Olichon

Franck Perez

Sandrine Moutel

Gilles Favre

Patrick Chinestra

Laura Keller

Nicolas Bery

The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Synthetic single domain antibody

The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.

Anti-rho GTPase conformational single domain antibodies and uses thereof

Anti-Rho GTPase conformational single domain antibodies and uses thereof

The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Growing community of inventors

Toulouse, France

Aurelien Olichon